Andere Sprachen Viracta Therapeutics, Inc.

Aktien

A2QQRS

US92765F1084

VIRX

Verzögert Nasdaq Andere Börsenplätze 19:02:05 25.04.2024			% 5 Tage	% 1. Jan.
0.821 ^USD	-1.83%		-9.78%	+43.88%

15.04.	Viracta Therapeutics, Inc. meldet positive Topline-Ergebnisse aus Phase 1 der zulassungsrelevanten Phase 2 NAVAL-1-Studie	CI
01.04.	Viracta Therapeutics präsentiert Topline-Ergebnisse von Nana-val aus Phase 1 der NAVAL-1-Studie auf dem Jahreskongress 2024 der Hematology Society of Taiwan	CI

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive Peripheral T-Cell Lymphoma	16.04.
Viracta Therapeutics Announces Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with Relapsed or Refractory Epstein-Barr Virus-Positive (EBV+) Peripheral T-Cell Lymphoma	15.04.
Viracta Therapeutics, Inc. Reports Positive Topline Results from Stage 1 of the Pivotal Phase 2 NAVAL-1 Trial	15.04.
Viracta Therapeutics : HST 2024 – Presentation	15.04.
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01.04.
Viracta Therapeutics to Present Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial at the 2024 Annual Congress of The Hematology Society of Taiwan	01.04.
Lenz Therapeutics, Graphite Bio Complete Merger; Combined Company Names New CFO	21.03.
Viracta Therapeutics, Inc. Announces Executive Changes	20.03.
Viracta Therapeutics, Inc. Announces Chief Financial Officer Changes	20.03.
North American Morning Briefing : Inflation -2-	15.03.
Sunesis: Q4 Earnings Snapshot	07.03.
Viracta Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07.03.
Viracta Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update	07.03.
Viracta Therapeutics, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	07.03.
Viracta Therapeutics Announces Completion of Second-Stage Enrollment into the Peripheral T-Cell Lymphoma Cohort of the NAVAL-1 Trial	29.02.
Viracta Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference	06.02.
Viracta Therapeutics, Inc. Provides Clinical Update	04.01.
Viracta Therapeutics Provides Clinical Update and Outlook for 2024	04.01.
Viracta Therapeutics Announces Orphan Drug Designation Granted by the U.S. FDA to Nana-val for the Treatment of Nasopharyngeal Carcinoma	12.12.
Viracta Therapeutics Announces Interim Data from Phase 1b/2 Clinical Trial of Nana-val in Patients with Epstein-Barr Virus-Positive Solid Tumors that Show Confirmed Tumor Responses at Higher Dose Levels	04.12.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Viracta Therapeutics, Inc.

Aktien

A2QQRS

US92765F1084

VIRX

Andere Sprachen

Filter